TCB008 for relapsed or refractory AML or MDS/AML
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new intravenous drug, TCB008, for people with acute myeloid leukemia (AML) or MDS/AML that has returned or not responded to previous treatments. The goal is to see if it is safe and if it can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and weigh at least 110 pounds (50 kg).
- You have AML or MDS/AML that has come back or not responded to at least one prior treatment.
- You are able to do daily activities on your own (ECOG score 0-2).
- Your liver, kidneys, heart, and blood counts are within acceptable ranges.
- You have not had a stem cell transplant or CAR-T therapy in the last 60 days, or if you have, you have no active side effects from it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a new medicine (ABD-3001) to see if it’s safe and tolerable, how the body handles it, and whether it shows early signs of helping people with relapsed or hard-to-treat AML or high-risk MDS. It may be an option if standard treatments have already failed and you can’t receive a stem cell transplant.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial tests a new drug, CRD3874-SI, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to see if this drug can help control the leukemia.
This trial tests a new cell therapy (BG1805) for children whose acute myeloid leukemia (AML) has returned or not responded to standard treatment. The therapy targets a specific marker on leukemia cells called CLL-1 and aims to help the immune system fight the cancer.
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.